CD43 is a highly glycosylated transmembrane protein expressed on the surface of most hematopoietic cells. Expression of CD43 has also been demonstrated in many human tumor tissues, including colon adenomas and carcinomas, but not in normal colon epithelium. The potential contribution of CD43 to tumor development is still not understood. Here, we show that overexpression of CD43 increases cell growth and colony formation in mouse and human cells lacking expression of either p53 or ARF (alternative reading frame) tumor-suppressor proteins. In addition, CD43 overexpression also lowers the detection of the FAS death receptor on the cell surface of human cancer cells, and thereby helps to evade FASmediated apoptosis. However, when both p53 and ARF proteins are present, CD43 overexpression activates p53 and suppresses colony formation due to induction of apoptosis. These observations suggest CD43 as a potential contributor to tumor development and the functional ARF-p53 pathway is required for the elimination of cells with aberrant CD43 expression.
Introduction
The CD43 molecule is a multifunctional type I transmembrane glycoprotein commonly expressed in hematopoietic cells (Remold-O'Donnell et al., 1984; Carlsson and Fukuda, 1986) . The 235 amino-acid extracellular domain of CD43 is heavily glycosylated and usually contains mainly sialylated O-linked glycans (Shelley et al., 1989) . Although the extracellular part of CD43 has an extended structure and negative charge, it can regulate cell adhesion both positively and negatively (Ardman et al., 1992; Ostberg et al., 1998) . The intracellular C-terminal domain of CD43 is evolutionary conserved and involved in signal transduction (Pallant et al., 1989; Shelley et al., 1989) .
The physiological roles of CD43 remain contradictory. In human T cells, ligation of CD43 with a monoclonal antibody (mAb) stimulated proliferative responses (Kyoizumi et al., 2004) , which could be triggered by activation of the mitogen-activated protein kinases p38 and extracellular signal-regulated kinase (Miura et al., 2001; Layseca-Espinosa et al., 2003) and Jun N-terminal kinase (Mattioli et al., 2004) . Engagement of CD43 can, depending on cell type, both induce and inhibit the DNA-binding activity of nuclear factor kappa B and affect the target gene expression (Brown et al., 1996; Santana et al., 2000; Laos et al., 2006) . Accordingly, CD43 exerts both positive and negative regulatory effects during an immune response (Woodman et al., 1998; Onami et al., 2002) . Moreover, CD43 regulates blood cell survival by inhibiting or enhancing apoptosis (He and Bevan, 1999; Cermak et al., 2002) .
CD43 has long been considered to be expressed only in hematopoietic cells, but in 1995, high levels of CD43 were detected in the human colon cancer cell line COLO205 (Baeckstrom et al., 1995) . Since then, CD43 expression has been found in several cancer cell lines of non-hematopoietic origin, such as cells of breast, lung, colonic, pancreatic and ovarian cancer (FernandezRodriguez et al., 2002; Ziprin et al., 2004) . Its expression has also been revealed in tissue sections from bladder, prostate, testis, lung, larynx and breast cancer (Santamaria et al., 1996) . CD43 expression occurs already in early stages of colorectal adenomas. However, there is no detectable CD43 expression in normal colon epithelium, suggesting a role in early tumor development Pimenidou et al., 2004) . Although the contribution of CD43 to tumor development is unclear, it has been suggested to alter cell adhesion, immune responses, cell growth and cell survival (Zhang et al., 1997; He and Bevan, 1999; Ziprin et al., 2004) .
p53 is one of the most commonly mutated genes found in human tumors (Levine, 1997) . The p53 protein is a tumor suppressor that negatively regulates neoplastic cell proliferation. It is a sequence-specific transcription factor that binds DNA and thereby activates or represses transcription from a large number of genes. Loss of p53 function in the cell leads to the dominance of proliferative signals promoting cancer development. Our previous study indicated that CD43 overexpression caused accumulation of transcriptionally active p53 tumor suppressor. CD43 did not induce p53 in cells lacking the tumor suppressor ARF (alternative reading frame), but introduction of ARF (p14ARF in human and p19ARF in mouse) restored the ability of CD43 to activate p53 leading to apoptosis (Kadaja et al., 2004) . Activation of the ARF-p53-signaling pathway occurs in response to oncogenic processes and is important for tumor suppression. These observations led us to the hypothesis that CD43 overexpression can induce activation of cell survival pathways and stimulate cell growth.
Here, we have examined the biological effects of CD43 in tumor cells by overexpressing CD43 in human and mouse cell lines of non-hematopoietic origin. The impact of CD43 overexpression on colony formation, cellular growth rate and apoptosis was studied. CD43 was shown to promote cell growth by increasing cell survival and colony formation in ARF/p53-dependent way. High CD43 expression also helped the cells to escape FAS-mediated apoptosis due to interference with the FAS receptors on the cell surface. Thus, CD43 can be considered as a molecule that might have a role in colon tumor development.
Results

CD43 overexpression affects colony formation
The tumor-suppressor protein p53 has been found to accumulate in the early phases of different tumors, including colon adenomas (Fearon and Vogelstein, 1990; Mazars et al., 1991) . Previously, we have shown that overexpression of CD43 caused accumulation of functionally active p53 protein, which was dependent on the presence of the tumor-suppressor protein ARF (Kadaja et al., 2004) . To further investigate the potential role of CD43 in tumor development, the effect of CD43 overexpression on colony formation was tested in different mouse and human cell lines lacking either p53 or ARF tumor suppressors. The cell lines used in this study are summarized in Table 1 . We used ARF-null mouse embryonic fibroblasts (MEFs), and the human colon carcinoma cell line HCT116, both expressing endogenous p53, but not ARF. In addition, two ARF-positive cell lines lacking p53 were used: MEFs 10(1) and the human non-small-cell lung carcinoma cell line H1299. We have assessed CD43 expression at both mRNA (quantitative PCR) and protein levels (flow cytometry analysis) in these cell lines. All these cell lines express low levels of endogenous CD43 (data not shown). To investigate the effect of increased levels of CD43 expression on cellular response, we provoked the elevated CD43 expression observed in colon adenomas by exogenous protein expression. The difference in levels of endogenous and exogenous CD43 proteins was about fivefold both in mouse and human cells (data not shown). The level of exogenous CD43 expression in mouse cells used is comparable with the level of endogenous CD43 expression in the human colorectal adenocarcinoma cell line COLO205, which is known to express high amounts of CD43, but in human cells, the CD43 expression is considerably higher (data not shown). The cells were transfected with CD43 or empty expression plasmid together with ARF or p53 expression plasmids. After 24 h, the cells were seeded at low density and grown until colonies were formed. Overexpression of CD43 suppressed the colony formation of all cell lines studied when both p53 and ARF proteins were present (Figures 1a-d) . In contrast, in cells lacking either ARF or p53, CD43 overexpression increased the colony formation compared to control cells. These results suggest that both p53 and ARF are required for the suppression of cell growth in response to CD43 overexpression. We also used siRNA-mediated gene silencing to knock down CD43 expression and observed that siRNA against CD43 led to a noticeable reduction in colony formation of H1299 and HCT116 cells as compared with the control siRNA (Figures 1e  and f) , confirming the role of CD43 in colony formation. However, the effect of siRNA against endogenous CD43 is more moderate compared to the cells with ectopic CD43 expression (Figures 1f and e, respectively), these observations are explicable by the low levels of endogenous CD43 in these cells.
CD43 overexpression induces p53/ARF-dependent apoptosis p53 is known to trigger ARF-dependent apoptosis in response to oncogene activation, which is important for tumor suppression (Lowe and Sherr, 2003) . Therefore, the p53-and ARF-dependent suppression of colony formation upon CD43 overexpression could be caused by the induction of cell death. To study this possibility, the cells were transfected as previously, stained with Annexin-V and analysed by flow cytometry. The percentage of apoptotic cells was increased by overexpression of CD43 when co-expressed with ARF in ARF-deficient cells (Figures 2a and c) and with p53 in p53-deficient cells (Figures 2b and d ). In accordance with our previous observations, CD43 overexpression caused an increase in the levels of p53 and ARF proteins as revealed by immunoblot analysis (Figure 2) . Thus, CD43 overexpression leads to the activation of tumor suppressors ARF and p53 that in turn results in cell death. Known oncogenes promote cell growth either by affecting the cell cycle or apoptosis. To study this, we performed cell cycle analysis by the bromodeoxyuridine incorporation assay. Besides HCT116 cells, we used the human cancer cell lines SW480 and MCF7, where CD43 was overexpressed under the control of the tetracycline-regulated promoter (Fernandez-Rodriguez et al., 2002; Kadaja et al., 2004) . Neither transiently transfected HCT116 cells nor tetracycline-induced SW480 and MCF7 cells showed any significant increase of cells in S phase when CD43 was overexpressed (data not shown). This suggests that CD43 may influence apoptotic signaling in the cells instead.
CD43 overexpression inhibits FAS-mediated apoptosis
FAS is a cell surface receptor, belonging to the tumor necrosis factor (TNF) receptor family, which mediates intracellular apoptosis signaling upon stimulation by its ligand, FASL (Nagata and Golstein, 1995) . The FAS Figure 1 CD43 overexpression suppresses the colony formation when both p53 and ARF are present, but the colony formation increases when either ARF or p53 is lacking. The ARF-null MEFs (a), 10(1) (b), HCT116 (c) and H1299 (d) cells were transfected with CD43 or with the empty vector either alone or together with the p53 or ARF vectors, replated at low density and selected with puromycin until colonies were formed. (e and f) Transient knockdown of CD43 in H1299 and HCT116 cells by siRNAs reduces colony formation. The effect of siRNA against exogenous (including endogenous) CD43 (cells designated CD43 þ þ in the figure) (e) and endogenous CD43 (f) was achieved by transfecting the siRNAs into cells together with additional transfection of CD43-expressing vector or without it (e and f, respectively). siRNA against b-catenin was used as a positive control. The post-transfection procedure was performed as described for (a-d). The obtained colonies were stained and counted under a microscope. The experiments were repeated three times and the results are presented relative to the empty vector or control siRNA-transfected cells.
CD43 promotes cell growth and inhibits FAS apoptosis L Kadaja-Saarepuu et al
receptor is expressed at high levels in normal epithelial cells, like in colon and breast, tissues which are sensitive to FAS-induced apoptosis. However, in colon and breast cancer cells, FAS is frequently downregulated and an impaired FAS-mediated apoptosis pathway has been shown to contribute to colon tumorigenesis (von Reyher et al., 1998; O'Connell et al., 2000) . It has previously been speculated that tumor cells could escape FAS-mediated cell death by expressing CD43 (He and Bevan, 1999) . To test the hypothesis that CD43 expression helps cancer cells to escape TNF receptorfamily-mediated, in particular FAS-mediated, apoptosis we used the CD43 overexpression system under regulation of tetracycline in SW480 and MCF7 cells. The level of CD43 expression achieved after induction in SW480/ CD43 cells is comparable with the endogenous CD43 expression levels in COLO205 cells (Fernandez-Rodriguez et al., 2002) . Tetracycline induction of MCF7/CD43 cells caused higher expression levels of CD43 than in SW480/CD43 cells.
The colon adenocarcinoma cell line SW480 is known to be susceptible to FAS-mediated apoptosis (Hewitt et al., 2000) . On the other hand, for the MCF7 breast cancer cells, only a sub-population of cells express FAS and therefore this cell line responds poorly to FASmediated apoptosis (Scaffidi et al., 1998) .
To trigger apoptosis, the SW480 cells were treated for 0 or 48 h with tetracycline (tet-on) and then for 11 h with 100 ng ml À1 anti-FAS mAb CH-11 (imitates the attachment of FASL to FAS receptor and induces apoptosis in cells) or 50 ng ml À1 TNFa in the medium. Control cells (0 and 48 h tet-on) not treated with anti-FAS mAb were kept in the medium only for the same time. The number of apoptotic cells was quantified on the basis of the 7-amino actinomycin D dye-exclusion test and Annexin-V staining followed by flow cytometry analysis. Incubation (Figure 4b ). These results indicate that both the SW480 and HCT116 cells expressing high levels of CD43 were protected from FAS-mediated apoptosis.
Decreased access of FAS in cancer cells overexpressing CD43
A common mechanism for cancer cells to decrease the sensitivity to FAS-induced apoptosis is to downregulate cell surface expression of FAS (Moller et al., 1994; Ivanov et al., 2003) . As CD43 overexpression protected the cells from FAS-mediated cell death in our experimental system, we next asked whether CD43 could . The trypsinized and resuspended cells were treated for 11 h with 100 ng ml À1 anti-FAS mAb CH-11 or 50 ng ml À1 tumor necrosis factor (TNF) a in medium or left untreated. Percentage of early and late apoptotic cells was assayed by using Annexin-V and 7-amino actinomycin D double staining by flow cytometry.
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affect the expression of FAS on tumor cells. First, we evaluated the cell surface expression of FAS in wild-type SW480 and MCF7 cells. Non-permeabilized cells were stained with anti-FAS mAb and analysed by flow cytometry. In both cell lines studied, expression of FAS receptor was detected on the cell surface (Figure 5a ). The expression of FAS on the cell surface was found to be more homogenously distributed in the SW480 cells as compared to the MCF7 cells. This correlates with the observation that SW480 cells are more susceptible to FAS-mediated apoptosis.
We next analysed the level of FAS at the cell surface in SW480 and MCF7 cells overexpressing CD43 or lacZ. Non-permeabilized 0 and 48 h tet-on cells were stained and analysed, as described previously. The results revealed that overexpression of CD43, but not lacZ, decreased the detection of FAS on the cell surface in both cell lines studied (Figures 5b and c) . To investigate whether the cytoplasmic tail of CD43 was sufficient to decrease FAS accessibility on the cell surface, we used the tetracyclineinducible expression of the cytoplasmic tail of CD43 coupled to GFP (GFP-CD43ct) in MCF7 cells. Overexpression of the cytoplasmic tail of CD43 did not affect cell surface expression of FAS (Figure 5d ), indicating that full-length CD43 was required to reduce FAS level at the cell surface. These results are in good correlation with the observations that CD43ct had no impact on cell growth and activation of ARF-p53 pathway (data not shown).
To explore whether CD43 regulates the level of FAS expression, we compared the total levels of FAS in 
MCF7 cells by flow cytometry. Non-permeabilized (detection of FAS expressed at the cell surface) and permeabilized (detection of total cellular FAS) 0 and 48 h tet-on MCF7/CD43 and MCF7/lacZ cells were stained with anti-FAS mAb and the amounts of FAS were estimated by flow cytometry. The results indicated that although CD43 overexpression reduced FAS on the cell surface, the total amount of FAS was not altered (Figure 6 ). To study the possibility that the highly glycosylated extracellular domain of CD43 might have affected the expression of other cell surface proteins, we analysed the MUC1 mucin. This molecule is similar to CD43, but has a longer extended highly glycosylated extracellular domain. No alterations in the amounts of cell surface MUC1 were observed upon CD43 overexpression (Figure 7a ). Another possibility is that CD43 by its large extended extracellular domain shields smaller molecules like integrins. The cell surface binding of antibodies against the integrins a6 and b1 was also not altered upon CD43 overexpression in MCF7 and SW480 cells (Figures 7b and c, respectively) . Together, these results suggest that the effect of CD43-mediated interference on the cell surface FAS is not due to a shielding effect of CD43.
Discussion
The expression of transmembrane glycoprotein CD43 has been described in different epithelial tumor cells, but its contribution to tumor development is still unknown. Here, we found that overexpression of CD43 promotes cell growth, cell survival and suppresses FAS-mediated apoptosis, but only in the absence of the tumor suppressors ARF or p53. This provides the first evidence that expression of CD43 in a certain cellular context may enhance the development of a transformed cell phenotype.
Several key alterations in the cell, such as activation of an oncogene or inactivation of a tumor-suppressor gene, are needed for tumorigenesis. This leads to an imbalance between cell growth and cell death. There are also several additional alterations in cancer cells caused by genes expressed at higher or lower levels than in normal cells. One such example is the glycoprotein CD43, which is not expressed in normal colon epithelial cells, but is commonly overexpressed in colorectal adenomas (Sikut et al., 1999; Pimenidou et al., 2004) .
Our previous study showed that elevation of CD43 levels caused accumulation of the transcriptionally active tumor-suppressor protein p53 in both human and mouse cell lines and this process was mediated by the tumor-suppressor protein ARF (Kadaja et al., 2004) . Induction of ARF expression has been described in response to a variety of proliferative signals. Activated ARF upregulates p53 through its inhibitory action on MDM2 and therefore causes cell death (Sherr and Weber, 2000) . Here, we show that overexpression of CD43 in the cells expressing both p53 and ARF reduces colony formation due to induction of apoptosis. Tumor cells have a selective pressure to lose the functionality of the tumor-suppressor proteins. Importantly, inactivation of the ARF expression is a frequent event in colon adenomas, suggesting that ARF suppresses colon cancer development at early stages (Esteller et al., 2000) . To Figure 7 CD43 overexpression does not decrease the exposed cell surface levels of MUC1 and integrins. CD43 overexpression does not alter the detection of MUC1 (a) and integrin a6 (b) at the cell surface of MCF7 cells. Cell surface staining of integrin b1 showed that CD43 overexpression had no effect on integrin b1 in SW480/ CD43 cells (c). Tetracycline non-treated cells are indicated by a thin line and 48 h tet-on cells by a bold line.
CD43 promotes cell growth and inhibits FAS apoptosis L Kadaja-Saarepuu et al test the hypothesis that CD43 expression in tumor cells may act as a cell growth and/or cell survival signal, we studied colony formation and cell growth in p53-or ARF-deficient cells. Under such cellular conditions, CD43 expression was found to promote cell growth and cell survival. As we did not detect any significant increase in the percentage of cells in S phase when CD43 was overexpressed, we suggest that CD43 rather affects cell viability than proliferation. This is in good correlation with previous observations that in transgenic mice where CD43 expression was induced in mature peripheral B lymphocytes (lacking CD43 in normal physiological conditions), CD43 increased cell viability due to decreased susceptibility to apoptosis (Dragone et al., 1995; Misawa et al., 1996) . The understanding of signaling pathways activated by CD43 in cancer cells is poor. Recently, CD43 was shown to interact with the oncogene b-catenin in cancer cells and was suggested to promote cell growth by upregulation of c-MYC and Cyclin D1 (Andersson et al., 2004) . Therefore, it is possible that CD43, maybe with the help of b-catenin, activate a signaling pathway responsible for this phenomenon.
Uncontrolled proliferation is not sufficient for tumor formation, but it must be linked to impaired apoptotic signaling. This is confirmed by the observations that deregulated cell growth alone can lead to apoptosis (Evan and Vousden, 2001 ). This was also the case with CD43 overexpression as shown in the present study. It is well established that CD43 functions as a regulator of apoptosis in hematopoietic cells, but it has been implicated in both antiapoptotic as well as proapoptotic processes (He and Bevan, 1999; Cermak et al., 2002) . It has been suggested that CD43 is a negative regulator of apoptosis during early hematopoiesis, but protects cells from apoptosis in more differentiated cells, as for example found in peripheral lymphocytes (Bazil et al., 1996 (Bazil et al., , 1997 Cermak et al., 2002) . Interestingly, highexpression levels of CD43 protected T-cell hybridoma cells against activation-induced cell death in mouse (He and Bevan, 1999) , which raised the possibility that CD43 expression can help tumor cells to escape FASmediated apoptosis. Moreover, CD43 expression levels have been found considerably increased in memory T cells of both human and mouse, whereas naive T cells showed downregulation of CD43, which sensitized them to apoptosis (He and Bevan, 1999) . These observations support the hypothesis that high CD43 expression levels, as found in tumor cells, may provide a mechanism for increased cell survival.
The mechanisms allowing resistance to FAS-mediated apoptosis in tumor cells are complex and defects have been identified at several levels of FAS signal transduction. Impairment of the FAS pathway has been described to be important for colon tumorigenesis (O'Connell et al., 2000) . In the present study, CD43 overexpression in tumor cell lines was found to reduce cell surface detection of FAS, which was dependent on the presence of the full-length CD43. As CD43 overexpression protected against FAS-mediated cell death in the cancer cell lines, it can be speculated that CD43 could be involved in evasion of FAS-dependent apoptosis in tumors. Recently, b-catenin has been reported to suppress activation of nuclear factor kappa B, which was linked to reduced FAS expression in colon and breast cancer cells (Deng et al., 2002) . Several other studies also suggest that one of the transcription factors necessary for FAS expression is nuclear factor kappa B p65 (Ouaaz et al., 1999; Zheng et al., 2001) . Interestingly, the cytoplasmic tail of CD43 has been found to interact with b-catenin, and overexpression of CD43 was linked to inhibition of the nuclear factor kappa B p65 DNA-binding activity and target gene expression (Andersson et al., 2004; Laos et al., 2006) , raising a possibility that CD43 could be involved in transcriptional regulation of FAS. Although the experiments to study the mRNA levels of FAS in CD43-overexpressing cells are not yet performed, our finding that the total level of FAS was not changed upon CD43 overexpression suggests that CD43 rather interferes with FAS at the post-translational level.
In summary, our findings provide the first evidence that CD43 overexpression promotes cell growth and viability and at the same time helps to evade FASmediated apoptosis. These findings support the idea that CD43 expression in early adenomas is important for colon tumor development .
Materials and methods
Cell culture and transfections
The cell lines used in this study are described in Table 1 . The cells were cultured at 5% CO 2 and 371C in Iscove's medium supplemented with 10% fetal bovine serum (Gibco-BRL, Roskilde, Denmark).
For transfection, the cells were seeded at 3 Â 10 5 cells per 60-mm dishes 24 h before transfection. The transfection reagent ExGene 500 (Fermentas, Vilmius, Lithuania) was used according to the manufacturer's instructions. The following expression plasmids were used: pQM-CD43; p53 (human), p14ARF and p19ARF cDNAs were cloned into pCG vector. pBabePuro contains the resistance gene for the antibiotic puromycin. The tetracycline-inducible overexpression system of CD43 and lacZ in MCF7 and SW480 cells has been characterized by Fernandez-Rodriguez et al. (2002) and Kadaja et al. (2004) . To generate MCF7/GFP-CD43ct cell lines, GFP-CD43ct cDNA was cloned into the pcDNA4/TO expression plasmid, transfected into MCF7/TR cells and stable clones selected by 50 mg ml À1 Zeocin. The protein overexpression was induced by 0.5 mg ml À1 tetracycline. Samples of siRNA for CD43 and b-catenin were purchased from Ambion (Austin, TX, USA). The sequences of siRNA oligomers are as follows: CD43, sense 5 0 -GCAAACUCUCU AGGAUCCCtt-3 0 and antisense 3 0 -gtCGUUUGAGAGAUC CUAGGG-5 0 ; b-catenin, sense 5 0 -GGUGGUGGUUAAUAA GGCUtt-3 0 and antisense 3 0 -gtCCACCACCAAUUAUUCC GA-5 0 . Cells (1.5 Â 10 5 ) were transfected with 3 mg siRNA using RNAiFect reagent (Qiagen, Hilden, Germany) according to the manufacturers' instructions. As a control, nonspecific siRNA oligomers (Ambion) were used.
Antibodies and western blot analysis
For detection of human CD43 on the cell surface, the mAb L10 reacting with the extracellular part of CD43 was a kind Western blot analysis was performed as described in Kadaja et al. (2004) . The primary antibodies used were anti-CD43 4D2 (Sikut et al., 1999) , anti-p53 DO-1 (Eurogenetics, Tessenderlo, Belgium), anti-p19ARF (Abcam Ltd, Cambridge, UK) and anti-p14ARF (Abcam Ltd) The secondary antibodies used were biotinylated sheep anti-mouse (DakoCytomation, Glostrup, Denmark), and biotinylated donkey anti-rabbit antibodies (Amersham Pharmacia Biotech, Uppsala, Sweden) and alkaline phosphatase conjugated with streptavidin (DakoCytomation). The signal was visualized with the solution of nitroblue tetrazolium (50 mg ml À1 ) and 5-bromo-4-chloro-3-indolyl phosphate (50 mg ml À1 ) in alkaline phosphatase buffer.
Cell growth assays
For colony-formation assay, the cells were transfected with pBabePuro together with indicated plasmids. Twenty-four hours after transfection, the cells were replated at low density (3 Â 10 3 cells per 60-mm plate) in triplicate and incubated in the presence of puromycin (0.3 mg ml À1 for human and 1 mg ml À1 for mouse cell lines) until colony formation (1-2 weeks). The colonies were fixed with 0.05% glutaraldehyde in phosphatebuffered saline, stained with Coomassie R-250 and the total number of colonies (defined as >15 cells) was counted.
For growth curves, the cells were transfected as indicated and grown under selective conditions of puromycin for 3 weeks and then seeded at 3.6 Â 10 4 cells per 60-mm tissue culture dish in triplicate for different time points. The cells were incubated and the number of cells per plate was determined by using a hemocytometer.
Flow cytometry analysis
To determine the cell surface levels of the proteins studied, 10 6 cells were incubated on ice for 45 min with 2 mg ml À1 antibodies in fluorescence-activated cell sorting (FACS) solution (2% bovine serum albumin in phosphate-buffered saline). Thereafter, the cells were washed and incubated on ice for 30 min with secondary antibody conjugated with Alexa-488 (Molecular Probes Inc., Karlsruhe, Germany) or APC (Caltag Laboratories, Burlingame, CA, USA). The cells were then washed and analysed with a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). For intracellular staining, the cells were incubated prior to primary antibody staining with 0.05% saponin containing FACS solution on ice for 30 min.
Cell viability and apoptosis
For apoptosis experiments, about 10 6 cells were seeded onto six-well plates and induced with tetracycline for indicated times. Then the cells were trypsinized, collected by centrifugation at 200 g for 5 min, and resuspended in a medium containing 10% fetal bovine serum, and tetracycline was added where indicated, 100 ng ml À1 agonistic anti-FAS mAb CH-11 (Nordic Biosite) or 50 ng ml À1 TNFa (R&D Systems, Abington, UK). The cells were incubated for 11 h with or without CH-11 or TNFa in medium and the control cells were just kept in medium. Apoptosis was determined by double staining cells with Annexin-V-PE (BD) and the 7-amino actinomycin D (Sigma Aldrich, St Louis, MO, USA) using flow cytometer. The number of cells stained positive with Annexin-V-PE (including early and late apoptotic cells) was presented. After transient transfections, apoptosis was detected 48 h post-transfection and analysed as described in Kadaja et al. (2004) .
